NCT04553692 2025-03-28Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersIGM Biosciences, Inc.Phase 1 Terminated272 enrolled
NCT03082209 2022-12-09A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic MalignanciesAbbViePhase 1 Completed153 enrolled